CLINICAL EFFICACY AND SAFETY OF TOLTERODINE COMPARED TO PLACEBO IN DETRUSOR OVERACTIVITY

Abstract

No AccessJournal of UrologyClinical Urology: Urological Neurology and Urodynamics1 May 1999CLINICAL EFFICACY AND SAFETY OF TOLTERODINE COMPARED TO PLACEBO IN DETRUSOR OVERACTIVITY RICHARD MILLARD, JOHN TUTTLE, KATE MOORE, JACQUES SUSSET, BARTON CLARKE, PETER DWYER, and BRADLEY E. DAVIS RICHARD MILLARDRICHARD MILLARD More articles by this author , JOHN TUTTLEJOHN TUTTLE More articles by this author , KATE MOOREKATE MOORE More articles by this author , JACQUES SUSSETJACQUES SUSSET More articles by this author , BARTON CLARKEBARTON CLARKE More articles by this author , PETER DWYERPETER DWYER More articles by this author , and BRADLEY E. DAVISBRADLEY E. DAVIS More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68951-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the efficacy, patient acceptability and side effect profile of tolterodine, a new antimuscarinic agent for treating bladder overactivity. Materials and Methods: In our randomized, placebo controlled, parallel group study 123, 129 and 64 patients 18 years old or older with proved detrusor overactivity (idiopathic detrusor instability or detrusor hyperreflexia) were randomized to receive 1 or 2 mg. tolterodine, or placebo, respectively, twice daily for 12 weeks. Main outcome measures were number of voids per 24 hours, urine volume per void and episodes of urge incontinence per 24 hours on a frequency-volume chart with detailed recording of side effects. Results: After 12 weeks of treatment mean number of voids per 24 hours plus or minus standard deviation decreased from 11.2 +/− 3.1 to 9.0 +/− 2.6 with the 2 mg. dosage (p = 0.0045 versus placebo). At this dose mean urine volume per void increased from 155 +/− 52 to 190 +/− 70 ml. (p <0.0001 versus placebo), while mean number of incontinence episodes per 24 hours decreased from 3.6 +/− 4.0 to 1.8 +/− 3.1 (p = 0.19 versus placebo). Similar efficacy was observed in patients receiving the 1 mg. dose. Severe dry mouth was reported by only 2, 1 and 2% of patients given the 1 and 2 mg. dose, and placebo, respectively. There was no clinical or electrocardiographic evidence of significant cardiac adverse events. Conclusions: Tolterodine administration resulted in a significant decrease in the frequency of voiding and improved voided volume but it was seldom associated with troublesome or severe side effects. References 1 : Current concepts in the treatment of disorders of micturition. Drugs1988; 35: 477. Google Scholar 2 : Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging1995; 6: 243. Google Scholar 3 : Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J. Urol.1991; 145: 813. Link, Google Scholar 4 : Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J. Urol.1988; 140: 47. Abstract, Google Scholar 5 : Anticholinergic therapy: the need for continued surveillance. Neurourol. Urodynam.1994; 13: 432. Google Scholar 6 : Tolterodine: a new bladder selective, muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci.1997; 60: 1129. Google Scholar 7 : Micturition pattern assessed by the frequency/volume chart in a healthy population of men and women. Neurourol. Urodynam.1989; 8: 421. Google Scholar 8 : Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Brit. J. Urol.1998; 81: 801. Google Scholar 9 : One way analysis of variance. In: . London: Chapman and Hall1991: 206. Google Scholar 10 : Oxybutynin chloride (3 mg) in the treatment of women with idiopathic detrusor instability. Brit. J. Urol.1990; 66: 479. Google Scholar 11 : Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Brit. J. Urol.1998; 81: 42. Google Scholar From the Departments of Urology, and Obstetrics and Gynaecology, University of New South Wales, Royal Women's Hospital, Brisbane and Melbourne, Australia, Urology Clinic, Lexington, Kentucky, Rhode Island Urodynamics, Inc., Providence, Rhode Island, and Mid-America Rehabilitation Hospital, Overland Park, KansasSupported by Pharmacia and Upjohn AB, Uppsala, Sweden.(Millard) Requests for reprints: Department of Urology, Prince Henry and Prince of Wales Hospitals, Sydney, 2036 Australia.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byGhei M, Miller R and Malone-Lee J (2018) Case Series Data to Encourage Randomized Trials of Bladder Retraining Compared to Antimuscarinic AgentsJournal of Urology, VOL. 175, NO. 4, (1411-1416), Online publication date: 1-Apr-2006.Amundsen C, Parsons M, Cardozo L, Vella M, Webster G and Coats A (2018) Bladder Diary Volume per Void Measurements in Detrusor OveractivityJournal of Urology, VOL. 176, NO. 6, (2530-2534), Online publication date: 1-Dec-2006.CHOO M, SONG C, KIM J, CHOI J, LEE J, CHUNG B and LEE K (2018) CHANGES IN OVERACTIVE BLADDER SYMPTOMS AFTER DISCONTINUATION OF SUCCESSFUL 3-MONTH TREATMENT WITH AN ANTIMUSCARINIC AGENT: A PROSPECTIVE TRIALJournal of Urology, VOL. 174, NO. 1, (201-204), Online publication date: 1-Jul-2005.HJALMAS K, ARNOLD T, BOWER W, CAIONE P, CHIOZZA L, von GONTARD A, HAN S, HUSMAN D, KAWAUCHI A, LÄCKGREN G, LOTTMANN H, MARK S, RITTIG S, ROBSON L, WALLE J and YEUNG C (2018) NOCTURNAL ENURESIS: AN INTERNATIONAL EVIDENCE BASED MANAGEMENT STRATEGYJournal of Urology, VOL. 171, NO. 6 Part 2, (2545-2561), Online publication date: 1-Jun-2004.MALONE-LEE J, SHAFFU B, ANAND C and POWELL C (2018) TOLTERODINE: SUPERIOR TOLERABILITY THAN AND COMPARABLE EFFICACY TO OXYBUTYNIN IN INDIVIDUALS 50 YEARS OLD OR OLDER WITH OVERACTIVE BLADDER: A RANDOMIZED CONTROLLED TRIALJournal of Urology, VOL. 165, NO. 5, (1452-1456), Online publication date: 1-May-2001.MUNDING M, WESSELLS H, THORNBERRY B and RIDEN D (2018) USE OF TOLTERODINE IN CHILDREN WITH DYSFUNCTIONAL VOIDING: AN INITIAL REPORTJournal of Urology, VOL. 165, NO. 3, (926-928), Online publication date: 1-Mar-2001.Greenfield S (2018) EDITORIAL: THE OVERACTIVE BLADDER IN CHILDHOODJournal of Urology, VOL. 163, NO. 2, (578-579), Online publication date: 1-Feb-2000. Volume 161Issue 5May 1999Page: 1551-1555 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.MetricsAuthor Information RICHARD MILLARD More articles by this author JOHN TUTTLE More articles by this author KATE MOORE More articles by this author JACQUES SUSSET More articles by this author BARTON CLARKE More articles by this author PETER DWYER More articles by this author BRADLEY E. DAVIS More articles by this author Expand All Advertisement PDF downloadLoading ...